Tiantan Bio

Historical price data

Tiantan Bio's mission is to ensure the supply of safe, effective, and high-quality biological products for public health in China. Its key achievements include establishing one of the nation's most extensive plasma collection networks and a sophisticated manufacturing platform for blood products and vaccines, making it a market leader in its core segments. The company's strategy is centered on deepening its plasma fractionation capabilities, expanding its vaccine portfolio, and advancing a pipeline of novel biologics to address unmet medical needs. Its position within the Sinopharm system provides significant strategic advantages in regulatory alignment and public health procurement.

Vertically integrated platform encompassing large-scale plasma collection, advanced cold ethanol fractionation and chromatographic purification, and stringent viral inactivation processes for producing plasma-derived therapies and vaccines.

Tiantan Bio competes in an oligopolistic domestic blood products market against a handful of large, state-affiliated players like China Biologic Products and Shanghai RAAS. Its competitive advantages are its scale, vertical integration, and unparalleled strategic position within the Sinopharm system, which creates high barriers to entry and ensures regulatory alignment.